Tag: NSPH

Blue Horseshoe Stocks: Friday Recap, DRL & More

Reviewing Friday’s Top Picks

iBio, Inc. IBIO

The number one mover from our Friday morning report was undoubtedly IBIO. Our recent observation that increasing concerns over the presence of the Ebola virus on American soil would drive related stocks paid off in spades.

IBIO was among those to get a huge boost on unconfirmed reports that it would aid in government efforts to speed production of the ZMapp experimental Ebola treatment.

The stock would see a low of .89 near the beginning of the session, and ended up running extremely hard into the close, reaching a high of 1.57. That equals out to an intraday surge of 76% but our total possible gains didn’t stop there. The stock continues to roll this morning, having hit a high of 2.76 in the premarket and pushing the total amount of the increase we’ve seen on IBIO since Friday morning to an impressive 210%


Alpha Pro Tech Ltd. APT

Like IBIO, APT was also affected by Ebola fears on Friday, and traded in a less extreme but similar pattern. After seeing a morning low of 5.72, the stock pushed the envelope into the close, reaching a peak of 7.43 for a 30% intraday gain. It is also gapping up bigtime today, with a premarket high of 9.25, which marks a 62% move up from Friday morning’s low.

Doral Financial Corp. DRL

Some of our more seasoned subscribers will certainly remember our coverage of DRL this year. We were waiting to get word on the company’s tax suit against the Puerto Rican governement, and Friday following market close, it was announced that the court has ruled in favor of Doral, which will be due the disputed-over sum of $229M.

As a result of this untraded-upon news, the stock is gapping up like crazy today, to the tune of a 9.46 premarket high, up well over 100% above the low we observed following our initial alert on DRL this summer.

We’ll probably see some selling pressure from profit taking in a situation like this, so we’ll be on the lookout for a potential dip-and-rip scenario to kick off the week.

Extended Watchlist:
AHPI, HEB, NSPH, SMED, FOMX, OBCI,

Blue Horseshoe Stocks: NSPH, DLIA, POWR

Nanosphere, Inc.  NSPH

NSPH is the first of a few new plays that we pulled off of our scanner this morning. The stock made a big move on Monday after it was learned that Nanoshpere had landed a substantial contract. Yesterday the company received FDA clearance on one of its products (Verigene(R) Enteric Pathogens Test), but could not maintain a steady run as a result of an overall dip in the markets.

The stock is, however, gapping up again this morning. We may want to keep an eye peeled for this play, as it is still trading near a relative bottom at its current price range; the stock was trading at 2.50 and above as recently as March.

dELIA*s, Inc. DLIA

Next up, we have DLIA, which popped up on our scanner as something of a momentum play. The stock is coming off of a recent bottom, and has been exhibiting the signs of a bullish run. A quick review of the chart shows that DLIA has made higher lows and higher highs for the last three consecutive trading sessions, and continued to build up a head of steam yesterday, pushing through its 50DMA.

We’re seeing a sizable gap-up this morning as well, and as you can see the chart still looks extremely bullish. We have an RSI which looks like its just about to punch into the power zone, and a MACD which recently underwent a bullish cross. If DLIA can now manage to break through the 200DMA (.98), it appears to have a pretty clear path on up to the 1.25-1.35 range.

PowerSecure International, Inc. POWR

Last but not least we have POWR, which is another morning gapper. The stock fell off a cliff on worse-than-expected earnings back in early May. We are now seeing some of that gap being filled, and want to keep a close watch over this play for the remainder of the week at the very least.

The gap on the chart goes all the way up to more than $18, so a return to previous levels would spell gains of more than 100% Even if the stock can manage to get back above its 50DMA (Currently 12.49), it would yield profits in excess of 40% over present prices.

Today the company announced it had successfully modified the service arrangement with one of its major utility customers to improve the terms of its ongoing service as outlined in the PR below.

WAKE FOREST, N.C., June 25, 2014 /PRNewswire/ — PowerSecure International, Inc. (POWR) today announced that it has successfully modified the service arrangement with one of its major utility customers to improve the terms of its ongoing service.  The modifications include adjustments to pricing, work assignments, and expected improvements in the ongoing scope of work. >> FULL PR


Extended Watchlist:
AERI, AMPE, BGMD, SYN, FB, TWTR

PROW, RNN & Extended Watchlist

Record-Setting ‘Green Rush’ Begins to Subside
–
Like all good things, the frenzied buying of countless pot stocks largely came to an end during yesterday’s session. It was a historic week; an overwhelming trend caused by sheer excitement over Colorado’s precedent-setting entry into the post-prohibition era, and we were happy to cover every step, taking profits along the way! Granted, the main wave of hysteria is now over, but our continued interest in the sector as a whole will not wane. As we stated previously, this story has only just begun to be written. Even as many of the huge runners we’ve tracked began to pull back, others maintained their trends, and still others came down to find support only to rebound and provide bounce opportunities. Rest assured, we will remain hot on the trail of any possible chance at added profits within this sector that has been so good to us for so long a time. For now, it’s time to shift gears and talk about some of our other interests that were forced to the back burner in all the excitement.

Progress Watch Corp. PROW

PROW has brought us some really impressive gains in the short time that we’ve been including it in our reports. When we first began talking about it (12/20/13, trading at .0065) we were especially interested in its tight share structure. That day, we said that the 50DMA rising sharply toward the 200DMA “should lead to a golden cross in the weeks and months ahead.”  That golden cross is now in progress as the stock ran into the close yesterday, attaining four cents, an increase of 515% off of the bottom we observed just twelve trading sessions ago.

As the value of the stock increases, we’re going to be looking for support levels to hold at areas of previous resistance. In the event of any pullbacks, we would like to see support hold at .025, and below that, .013, in order to remain bullish on PROW.

Rexhan Pharmaceuticals, Inc. RNN

Back on December 11th, we tagged RNN for the first time in our extended watchlist, and were rewarded with an intraday run of 26% from .4026 to  .5179. Even as marijuana stocks were breaking out over the past couple of days, we were still tracking this stock’s impressive run via our extended watchlists, and yesterday, saw a high of .765. That marks an increase of 90% from our observed low, a figure which is being pushed even higher this morning; pre-market trades have gone off as high as .929, so things could get very interesting from here. This spike seems to have been catalyzed by a recent press announcement from RNN.


The following PR was released under the headline: “RX-3117 has Shown Efficacy Against Gemcitabine-Resistant Human Cancer Cell Lines and a Broad-Spectrum of Anti-Cancer Activity “

ROCKVILLE, Md., Jan 08, 2014 (BUSINESS WIRE) — Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors. RX-3117 is a next-generation cancer cell specific drug candidate that possesses a broad spectrum of anticancer activity with reduced side effects. In an exploratory Phase I clinical trial conducted in Europe, RX-3117 demonstrated oral bioavailability, and safety and tolerability in cancer patients with solid tumors. >> FULL PR

Extended Watchlist:
CNAT, BBRY, IMMU, BLDP, NSPH, RTRX